Strategic Advisor - AI in Oncology

About Burna AI

Burna AI is building the safety and data quality platform for oncology drug development, from

clinical trials through postmarket surveillance.

We started with the single most painful workflow in drug safety: adverse event grading. Manual

CTCAE grading takes trained research coordinators 15 to 20 minutes per adverse event, with 20 to 30% inter-rater variability and no standardization across sites. Our CTCAE AI platform

reduces that to seconds, with strong agreement with expert clinicians, zero hallucinations by

design, and human-in-the-loop always.

The platform includes multi-drug causality attribution using WHO-UMC and Kramer

algorithms, 42 pre-built oncology regimen profiles, comorbidity-aware grading, batch clinical

note processing, and integration with Epic, Oracle Health, Medidata, and Veeva Vault EDC via

SMART on FHIR. We are HIPAA compliant, SOC 2 certified, and 21 CFR Part 11 aligned.

Burna AI has been accepted into a top-tier cancer center accelerator program with access to

1,200+ patient charts across multiple campuses, is a member of CancerX (the HHS Cancer

Moonshot public-private partnership), and has filed two patents. We are closing a $3M SAFE

seed round.

Learn more at

Role Overview

We are assembling a select group of Strategic Advisors with deep experience at the intersection

of oncology, artificial intelligence, and clinical data systems. This is a board-level advisory role for senior clinicians, physician-executives, and healthcare technology leaders who want to shape howAI is applied to drug safety, not in theory, but in production at leading cancer centers.

This role is best suited for advisors who have led or participated in AI adoption within clinical or

research settings and who understand the gap between a working model and a deployed system that clinicians trust.

Key Responsibilities

AI Strategy and Clinical Direction Advise on the application ofAI and machine learning to

CTCAE grading, multi-drug causality attribution, and safety data quality across the oncology

drug lifecycle.

Clinical Validation and Adoption Guide validation study design, safety considerations, and the

path from internal testing to peer-reviewed publication. Our immediate priority is executing our

lead cancer center validation study and targeting JCO and JAMIA.

Workflow and Usability Insight Ensure the platform aligns with real clinical workflows,

minimizing clinician burden while maintaining accuracy, compliance, and trust. AI suggests,

clinicians decide.

Enterprise and Platform Thinking Support decisions on scaling across cancer centers and

health systems, including EHR integration, two-sided business model design (provider SaaS

plus pharma data quality services), and postmarket pharmacovigilance expansion.

Thought Leadership Contribute to publications, conference presentations, or advisory

discussions on AI in oncology drug safety. Co-authorship eligibility on implementation studies.

Strategic Network Support Where appropriate, facilitate introductions to oncology leaders,

digital health innovators, academic partners, or investors.

Ideal Candidate Profile

• Senior clinician, physician-executive, or healthcare technology leader with oncology or drug safety domain expertise
• Direct experience with AI/ML deployment, clinical informatics, or digital health adoption in healthcare settings
• Familiarity with clinical trial operations, EHR environments, and the challenges of enterprise technology adoption in academic medical centers
• Understanding of regulatory landscape (FDA, 21 CFR Part 11, CTCAE standards)
• Prior advisory board, innovation committee, or clinical informatics leadership experience preferred
• Strategic mindset with comfort operating at a board level

Time Commitment

• Approximately 2 to 4 hours per month (advisory sessions plus async review)
• Fully remote, flexible engagement

Compensation and Benefits

• Equity participation aligned with advisory contribution
• Opportunity to participate in Burna AI's seed financing round ($3M SAFE)
• Co-authorship eligibility on validation studies and implementation publications
• Direct impact on building the safety data quality layer for oncology drug development
• Collaboration with a 20+ member advisory board spanning clinical, pharma, regulatory, and technology leadership

Equal Opportunity Statement

Burna AI is committed to building a diverse and inclusive advisory board. We welcome

candidates from all backgrounds and value perspectives that reflect the communities we serve.